ADVERTISEMENT
Cipla Announces Closure Of U.S. FDA Inspection At Bengaluru Facility
Cipla announces closure of U.S. FDA inspection at Bengaluru facility.
22 Sep 2019, 06:13 PM IST 
An employee arranges medicine bottles during the manufacture of pharmaceuticals (Photographer: Akos Stiller/Bloomberg)
Cipla Ltd. today announced the closure of inspection by the U.S. health regulator at the company's API manufacturing facility in Bengaluru.
"Following the inspection by the United States Food and Drug Administration at the company's API manufacturing facility in Virgonagar, Bengaluru, from July 15-19, 2019, the company has received the Establishment Inspection Report, indicating closure of the inspection," the company said in a filing to the BSE.
The company had earlier said that U.S. FDA issued seven observations after conducting a routine 'Current Goof Manufacturing Practice inspection' at Cipla's API manufacturing facility in Virgonangar, Bengaluru.